NeoImmuneTech, Inc. (KOSDAQ:A950220) announced that it has received $4,700,000 in funding led by Kindstar Global (Beijing) Technology, Inc. on November 25, 2021. The transaction included participation from Hefei SPARK Venture Capital Management Co., Ltd.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.51 HKD | -3.21% |
|
-5.03% | -10.12% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.12% | 190M | |
-15.37% | 8.55B | |
+68.94% | 4.23B | |
+3.72% | 2.68B | |
+0.35% | 2.61B | |
-55.09% | 1.82B | |
-18.60% | 1.66B | |
-21.23% | 1.42B | |
+15.60% | 1.19B | |
-49.14% | 1.05B |
- Stock Market
- Equities
- 9960 Stock
- News Kindstar Globalgene Technology, Inc.
- NeoImmuneTech, Inc. announced that it has received $4.7 million in funding from Hefei SPARK Venture Capital Management Co., Ltd., Kindstar Global Technology, Inc.